Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409008 | 0.99 | OPRM1 (0.39) | OPRM1OPRD1MMP1MMP13MMP9 | |
| SCHEMBL6409601 | 0.93 | CCR5 (0.38) | OPRM1OPRD1MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6413215 | 0.92 | CCR5 (0.38) | OPRM1OPRD1MMP1MMP13MMP9 | |
| SCHEMBL6410548 | 0.92 | MMP1 (0.40) | OPRM1OPRD1MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6410546 | 0.91 | MMP1 (0.39) | OPRM1OPRD1MMP1MMP13MMP9 | |
| SCHEMBL6417580 | 0.91 | MEN1 (0.39) | OPRM1OPRD1MMP1MMP13MMP9 | |
| SCHEMBL6409816 | 0.90 | CCR5 (0.39) | OPRM1OPRD1MMP1MMP13MMP9 | |
| SCHEMBL6410498 | 0.90 | CCR5 (0.39) | OPRM1OPRD1MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6417578 | 0.90 | MEN1 (0.38) | OPRM1OPRD1MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6412431 | 0.90 | CCR5 (0.38) | OPRM1OPRD1MMP1MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | OPRM1 244/4885OPRD1 177/4885MMP1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.